Cytokinetics Inc
XMUN:KK3A
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Cytokinetics Inc
XMUN:KK3A
|
US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
US |
Intrinsic Value
The intrinsic value of 
Cytokinetics Inc (KK3A) under the Base Case is 35.07 EUR per share.
Compared with the current market price of 55.02 EUR, the stock appears
Overvalued by 36% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Cytokinetics Does
Cytokinetics is a drug development company focused on diseases where muscles do not work properly, especially heart and skeletal muscle disorders. It designs medicines that affect the way muscle fibers contract, with a strong emphasis on treatments for heart failure and some rare neuromuscular conditions.
- Headquarters
- United States of America US
- Employees
- 673
- IPO date
- Apr 29, 2004
Cytokinetics has no economic moat
Clinicians can choose other treatments for obstructive HCM, and one patient’s use of MYQORZO does not make it more valuable to other patients. Cytokinetics has no built-in user network or customer lock-in that prevents rival medicines from competing for prescriptions.
Read the full moat analysis
Revenue & Expenses Breakdown
Cytokinetics Inc
Earnings Waterfall
Cytokinetics Inc
The intrinsic value for Cytokinetics Inc (KK3A) under the Base Case is 35.07 EUR.
Compared with the current market price of 55.02 EUR, the stock appears Overvalued by 36% .